HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress
HighTide Therapeutics announced that it will present at the EASL Congress 2025. The presentations include New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010).
April 25, 2025
by ACN Newswire
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes Mellitus.
April 16, 2025
by ACN Newswire
HighTide Therapeutics Announces Publication of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus Open
HighTide Therapeutics announced that Phase 2 data of berberine ursodeoxycholate for treating T2DM was published in JAMA Network Open.
March 5, 2025
by ACN Newswire
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress
Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
June 5, 2024
by PharmaSources
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
HighTide Therapeutics Inc. announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
January 12, 2023
by PharmaSources
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
HighTide Therapeutics announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund.
January 5, 2023
by PharmaSources.com
HighTide Therapeutics Receives Fast Track Designation for HTD1801
HighTide Therapeutics announced the FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholangitis (PSC).
September 29, 2018
by americanpharmaceuticalreview